acitretin has been researched along with imiquimod in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 4 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Difonzo, EM; Giannotti, B; Pimpinelli, N; Vanzi, L | 1 |
| Ingves, C; Jemec, GB | 1 |
| Atkins, CL; Brown, VL; Cerio, R; Ghali, L; Harwood, CA; Proby, CM | 1 |
| Haustein, UF; Paasch, U | 1 |
| Duvic, M; Hicks, LD | 1 |
| Basar, H; Bozdogan, O; Emeksiz, MC; Erkek, E | 1 |
| Delaney, T; Foxton, G | 1 |
| Barysch, MJ; Dummer, R; Kamarashev, J; Lockwood, LL | 1 |
| Aguayo, R; Baradad, M; Casanova, JM; Sanmartín, V | 1 |
| Hugh, JM; Nijhawan, RI; Osei-Tutu, A | 1 |
| Alaibac, M; Peserico, A; Piaserico, S; Sandini, E | 1 |
| Chong, WS; Lim, JH; Lim, KS | 1 |
| Caglia, M; Hashemi, P; Kim, C; Shulman, K | 1 |
| Brennand, S; Chong, AH; Fahey, V; Goh, MS; Maor, D; Tabrizi, SN | 1 |
| Gao, Q; Liu, JH; Luo, DQ; Wang, F; Wu, HH; Zhao, YK | 1 |
| Guo, J; He, F; Long, F; Tu, J; Yin, Z | 1 |
| Belda, W; Criado, PR; Domingues Passero, LF | 1 |
| Moore, S; Rady, P; Tyring, S | 1 |
| Belda, W; Casolato, ATS; Luppi, JB; Passero, LFD | 1 |
3 review(s) available for acitretin and imiquimod
| Article | Year |
|---|---|
Combined imiquimod and acitretin for non-surgical treatment of basal cell carcinoma.
Topics: Acitretin; Algorithms; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Basal Cell; Drug Synergism; Female; Humans; Imiquimod; Middle Aged; Skin Neoplasms; Treatment Outcome | 2003 |
Cutaneous viral infections in organ transplant patients.
Topics: Acitretin; Administration, Cutaneous; Aminoquinolines; Antiviral Agents; Cidofovir; Cytosine; Dermatologic Agents; Hair Diseases; Herpes Simplex; Herpes Zoster; Humans; Ichthyosis; Imiquimod; Immunocompromised Host; Immunosuppressive Agents; Incidence; Italy; Molluscum Contagiosum; Organ Transplantation; Organophosphonates; Skin Diseases, Viral; Transplant Recipients; Warts | 2014 |
Acquired epidermodysplasia verruciformis: clinical presentation and treatment update.
Topics: Acitretin; Cidofovir; Epidermodysplasia Verruciformis; HIV Infections; Humans; Imiquimod; Mycophenolic Acid; Papillomaviridae; Papillomavirus Infections; Vaccines | 2022 |
1 trial(s) available for acitretin and imiquimod
| Article | Year |
|---|---|
Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial.
Topics: Acitretin; Adjuvants, Immunologic; Administration, Topical; Adult; Aged; Aminoquinolines; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Double-Blind Method; Female; Humans; Imiquimod; Immunosuppression Therapy; Keratolytic Agents; Kidney Transplantation; Male; Middle Aged; Ointments; Precancerous Conditions; Risk Factors; Skin; Skin Neoplasms | 2005 |
16 other study(ies) available for acitretin and imiquimod
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The treatment of basal cell carcinomas in a patient with xeroderma pigmentosum with a combination of imiquimod 5% cream and oral acitretin.
Topics: Acitretin; Administration, Oral; Administration, Topical; Adolescent; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Drug Therapy, Combination; Facial Neoplasms; Humans; Imiquimod; Keratolytic Agents; Male; Treatment Outcome; Xeroderma Pigmentosum | 2003 |
Aggressive undifferentiated squamous cell carcinoma in an immunosuppressed patient after kidney transplantation.
Topics: Acitretin; Adjuvants, Immunologic; Administration, Oral; Aminoquinolines; Antineoplastic Agents; Carcinoma, Squamous Cell; Counseling; Cyclosporine; Follow-Up Studies; Humans; Imiquimod; Immunocompromised Host; Immunosuppressive Agents; Keratolytic Agents; Keratosis; Kidney Transplantation; Male; Middle Aged; Ointments; Skin; Skin Neoplasms; Sunscreening Agents; Time Factors | 2005 |
Wiskott-Aldrich syndrome and molluscum contagiosum: a therapeutic challenge after reaction to cidofovir.
Topics: Acitretin; Adjuvants, Immunologic; Administration, Oral; Administration, Topical; Adult; Aminoquinolines; Antiviral Agents; Cidofovir; Cytosine; Drug Resistance; Humans; Imiquimod; Immunocompromised Host; Lymphoma, Large B-Cell, Diffuse; Male; Molluscum Contagiosum; Organophosphonates; Wiskott-Aldrich Syndrome | 2008 |
Giant condyloma acuminata of Buschke-Löwenstein: successful treatment with a combination of surgical excision, oral acitretin and topical imiquimod.
Topics: Acitretin; Administration, Oral; Administration, Topical; Aminoquinolines; Combined Modality Therapy; Condylomata Acuminata; Drug Therapy, Combination; Humans; Imiquimod; Keratolytic Agents; Male; Middle Aged; Penile Diseases | 2009 |
Eruptive keratoacanthoma and squamous cell carcinoma complicating imiquimod therapy: response to oral acitretin.
Topics: Acitretin; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Humans; Imiquimod; Keratoacanthoma; Keratolytic Agents; Skin Neoplasms; Treatment Outcome | 2011 |
Successful treatment of multiple keratoacanthoma with topical imiquimod and low-dose acitretin.
Topics: Acitretin; Administration, Oral; Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Female; Humans; Imiquimod; Keratoacanthoma; Keratolytic Agents; Skin Neoplasms | 2011 |
[Oral acitretin and topical imiquimod as neoadjuvant treatment for giant basal cell carcinoma].
Topics: Acitretin; Administration, Cutaneous; Administration, Oral; Aged; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Basal Cell; Combined Modality Therapy; Facial Neoplasms; Female; Humans; Imiquimod; Neoadjuvant Therapy; Psoriasis; Remission Induction; Skin Neoplasms; Skin Ulcer; Thoracic Neoplasms | 2012 |
Sustained clinical resolution of acquired epidermodysplasia verruciformis in an immunocompromised patient after discontinuation of oral acitretin with topical imiquimod.
Topics: Acitretin; Adjuvants, Immunologic; Administration, Cutaneous; Administration, Oral; Aminoquinolines; Epidermodysplasia Verruciformis; HIV Infections; Humans; Imiquimod; Immunocompromised Host; Keratolytic Agents; Male; Middle Aged; Treatment Outcome | 2013 |
Dramatic clearance of HIV-associated bowenoid papulosis using combined oral acitretin and topical 5% imiquimod.
Topics: Acitretin; Administration, Cutaneous; Administration, Oral; Adult; Aminoquinolines; Anal Canal; Antineoplastic Agents; Bowen's Disease; Drug Therapy, Combination; HIV Infections; Humans; Imiquimod; Keratolytic Agents; Male; Skin Neoplasms | 2014 |
Treatment of Imiquimod Resistant Epidermodysplasia Verruciformis With Ingenol Mebutate.
Topics: Acitretin; Adult; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Diterpenes; Drug Resistance; Epidermodysplasia Verruciformis; Female; Gels; Humans; Imiquimod; Keratolytic Agents; Rare Diseases; Skin Neoplasms; Treatment Outcome; Tretinoin | 2016 |
A case of acquired epidermodysplasia verruciformis in a renal transplant recipient clearing with multimodal treatment including HPV (Gardasil) vaccination.
Topics: Acitretin; Adjuvants, Immunologic; Drug Therapy, Combination; Epidermodysplasia Verruciformis; Female; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Humans; Imiquimod; Immunosuppression Therapy; Keratolytic Agents; Kidney Transplantation; Middle Aged; Tretinoin | 2018 |
Thalidomide Improves Psoriasis-like Lesions and Inhibits Cutaneous VEGF Expression without Alteration of Microvessel Density in Imiquimod- induced Psoriatic Mouse Model.
Topics: Acitretin; Angiogenesis Inhibitors; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Female; Imiquimod; Mice, Inbred BALB C; Microvessels; Neovascularization, Pathologic; Psoriasis; Signal Transduction; Skin; Thalidomide; Vascular Endothelial Growth Factor A | 2018 |
Acitretin inhibits IL-17A-induced IL-36 expression in keratinocytes by down-regulating IκBζ.
Topics: Acitretin; Animals; Anti-Inflammatory Agents; Cell Line; Disease Models, Animal; Down-Regulation; Female; Humans; I-kappa B Kinase; Imiquimod; Interleukin-1; Interleukin-17; Keratinocytes; Mice; Mice, Inbred BALB C; Psoriasis | 2020 |
Case Report: Treatment of Chromoblastomycosis with Combinations including Acitretin: A Report of Two Cases.
Topics: Acitretin; Adjuvants, Immunologic; Antifungal Agents; Chromoblastomycosis; Drug Therapy, Combination; Humans; Imiquimod; Itraconazole; Keratolytic Agents; Male; Middle Aged | 2020 |
Managing chromoblastomycosis with acitretin plus imiquimod: A case report on the improvement of cutaneous lesions and reduction of the treatment time.
Topics: Acitretin; Chromoblastomycosis; Humans; Imiquimod; Plastic Surgery Procedures | 2021 |